Venous access catheter-related thrombosis in patients with cancer

References

• Munoz FJ, Mismetti P, Poggio R, et al. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008;133:143–148.
   PubMed Web of Science ®Google Scholar
• Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585–593.
   PubMed Web of Science ®Google Scholar
• Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809–815.
   PubMed Web of Science ®Google Scholar
• Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293: 715–722.
   PubMed Web of Science ®Google Scholar
• Farge D, Durant C, Villiers S, et al. Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients. Thromb Res 2010;125(Suppl. 2):S108–S116.
   Web of Science ®Google Scholar
• Yildizeli B, Lacin T, Batirel HF, et al. Complications and management of long-term central venous access catheters and ports. J Vasc Access 2004;5:174–178.
   PubMedGoogle Scholar
• Joffe HV, Kucher N, Tapson VF, et al. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 2004;110:1605–1611.
   PubMed Web of Science ®Google Scholar
• Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003;21:3665–3675.
   PubMed Web of Science ®Google Scholar
• Feliu J, Lecumberri R, Jerez A, et al. Incidence of deep venous thrombosis associated with central venous catheters (DVT-CVC) in cancer patients: A multicenter studyI. J Clin Oncol 2006;24(18 Suppl.): Abstract 8627.
   Web of Science ®Google Scholar
• Prandoni P, Polistena P, Bernardi E, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997;157:57–62.
   PubMed Web of Science ®Google Scholar
• Monreal M, Lafoz E, Ruiz J, et al. Upper-extremity deep venous thrombosis and pulmonary embolism. A prospective study. Chest 1991;99:280–283.
   Google Scholar
• Monreal M, Davant E. Thrombotic complications of central venous catheters in cancer patients. Acta Haematol 2001;106:69–72.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004;9:207–216.
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter–related thrombosis in adult patients with cancer. J Clin Oncol 2006;24:1404–1408.
   PubMed Web of Science ®Google Scholar
• Chopra V, Anand S, Hickner A, et al. Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet2013 May 17. [Epub ahead of print]
   Google Scholar
• Agnelli G, Verso M. Therapy Insight: venous-catheter-related thrombosis in cancer patients. Nat Clin Pract Oncol 2006;3: 214–222.
   PubMedGoogle Scholar
• Curelaru I, Gustavsson B, Hansson AH, et al. Material thrombogenicity in central venous catheterization II. A comparison between plain silicone elastomer, and plain polyethylene, long, antebrachial catheters. Acta Anaesthesiol Scand 1983;27:158–164.
   PubMed Web of Science ®Google Scholar
• Linder LE, Curelaru I, Gustavsson B, et al. Material thrombogenicity in central venous catheterization: a comparison between soft, antebrachial catheters of silicone elastomer and polyurethane. JPEN J Parenter Enteral Nutr 1984;8:399–406.
   PubMed Web of Science ®Google Scholar
• Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients. J Clin Oncol 1995;13:233–238.
   PubMed Web of Science ®Google Scholar
• Cavanna L, Civardi G, Vallisa D, et al. Ultrasound-guided central venous catheterization in cancer patients improves the success rate of cannulation and reduces mechanical complications: a prospective observational study of 1,978 consecutive catheterizations. World J Surg Oncol 2010;8:91.
   PubMed Web of Science ®Google Scholar
• Brown-Smith JK, Stoner MH, Barley ZA. Tunneled catheter thrombosis: factors related to incidence. Oncol Nurs Forum 1990;17:543–549.
   PubMedGoogle Scholar
• De Cicco M, Matovic M, Balestreri L, et al. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res 1997;86:101–113.
   PubMed Web of Science ®Google Scholar
• Cortelezzia A, Fracchiolla NS, Maisonneuve P, et al. Central venous catheter-related complications in patients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures. Leuk Lymphoma 2003;44:1495–1501.
   PubMed Web of Science ®Google Scholar
• Tran H, Arellano M, Chamsuddin A, et al. Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters. Leuk Lymphoma 2010;51:1473–1477.
   PubMed Web of Science ®Google Scholar
• Saber W, Moua T, Williams EC, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost 2011;9:312–319.
   PubMed Web of Science ®Google Scholar
• McLean TW, Fisher CJ, Snively BM, et al. Central venous lines in children with lesser risk acute lymphoblastic leukemia: optimal type and timing of placement. J Clin Oncol 2005;23:3024–3029.
   PubMed Web of Science ®Google Scholar
• Kuriakose P, Colon-Otero G, Paz-Fumagalli R. Risk of deep venous thrombosis associated with chest versus arm central venous subcutaneous port catheters: a 5-year single-institution retrospective study. J Vasc Interv Radiol 2002;13:179–184.
   PubMed Web of Science ®Google Scholar
• Schwarz RE, Coit DG, Groeger JS. Transcutaneously tunneled central venous lines in cancer patients: an analysis of device-related morbidity factors based on prospective data collection. Ann Surg Oncol 2000;7:441–449.
   PubMed Web of Science ®Google Scholar
• Luciani A, Clement O, Halimi P, et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 2001;220:655–660.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Yun J, Kim KH, et al. Safety and effectiveness of central venous catheterization in patients with cancer: prospective observational study. J Korean Med Sci 2010;25:1748–1753.
   PubMed Web of Science ®Google Scholar
• van Rooden CJ, Schippers EF, Barge RM, et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005;23:2655–2660.
   PubMed Web of Science ®Google Scholar
• Mehall JR, Saltzman DA, Jackson RJ, et al. Fibrin sheath enhances central venous catheter infection. Crit Care Med 2002;30:908–912.
   PubMed Web of Science ®Google Scholar
• Gale AJ, Gordon SG. Update on tumor cell procoagulant factors. Acta Haematol 2001;106:25–32.
   PubMed Web of Science ®Google Scholar
• Gouin-Thibault I, Achkar A, Samama MM. The thrombophilic state in cancer patients. Acta Haematol 2001;106:33–42.
   PubMed Web of Science ®Google Scholar
• Scialla SJ, Speckart SF, Haut MJ, et al. Alterations in platelet surface sialytransferase activity and platelet aggregation in a group of cancer patients with a high incidence of thrombosis. Cancer Res 1979;39:2031–2035.
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Moia M, Falanga A, et al. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol 2005;129:811–817.
   PubMed Web of Science ®Google Scholar
• De Cicco M, Matovic M, Balestreri L, et al. Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer patients. Thromb Res 1995;78:127–137.
   PubMed Web of Science ®Google Scholar
• Wermes C, von Depka Prondzinski M, Lichtinghagen R, et al. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 1999;158(Suppl. 3):S143–S146.
   Web of Science ®Google Scholar
• Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107:I17–I21.
   PubMed Web of Science ®Google Scholar
• Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977;56:1–37.
   PubMed Web of Science ®Google Scholar
• Lieberman JS, Borrero J, Urdaneta E, et al. Thrombophlebitis and cancer. JAMA 1961;177:542–545.
   PubMed Web of Science ®Google Scholar
• Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285–291.
   PubMed Web of Science ®Google Scholar
• Goodnough LT, Saito H, Manni A, et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984;54:1264–1268.
   PubMed Web of Science ®Google Scholar
• Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286–294.
   PubMed Web of Science ®Google Scholar
• Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004;164:190–194.
   PubMed Web of Science ®Google Scholar
• Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404–407.
   PubMed Web of Science ®Google Scholar
• Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006;118:555–568.
   PubMed Web of Science ®Google Scholar
• Cool RM, Herrington JD, Wong L. Recurrent peripheral arterial thrombosis induced by cisplatin and etoposide. Pharmacotherapy 2002;22:1200–1204.
   PubMed Web of Science ®Google Scholar
• Licciardello JT, Moake JL, Rudy CK, et al. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985;42: 296–300.
   PubMed Web of Science ®Google Scholar
• Oner AF, Gurgey A, Kirazli S, et al. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase. Leuk Lymphoma 1999;33:361–364.
   PubMed Web of Science ®Google Scholar
• Kinhult S, Albertsson M, Eskilsson J, et al. Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation. Scanning 2001;23:1–8.
   PubMed Web of Science ®Google Scholar
• Cwikiel M, Eskilsson J, Albertsson M, et al. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol 1996;7:731–737.
   PubMed Web of Science ®Google Scholar
• Gobel U, Ebell W, Jiirgens H, et al. Coagulation changes following bleomycin treatment in animals. Proc Am Soc Clin Oncol 1983;2(Suppl.): Abstract 39.
   Google Scholar
• Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990;112:423–428.
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90: 1371–1388.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817–824.
   PubMed Web of Science ®Google Scholar
• Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93–97.
   PubMed Web of Science ®Google Scholar
• Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98–101.
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–62.
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565–1571.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050–4053.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Weber D, Chen C, et al. Evaluating oral lenalidomide (Revlimid) and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica 2005;90(Suppl.): Abstract 160.
   Google Scholar
• Chavez-MacGregor M, Zhao H, Fang S, et al. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. Cancer 2011;117:3641–3649.
   PubMed Web of Science ®Google Scholar
• Dusenbery KE, McGuire WA, Holt PJ, et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994;29:1079–1084.
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Grassi A, et al. Thrombosis in cancer patients treated with hematopoietic growth factors--a meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1996;75:368–371.
   PubMed Web of Science ®Google Scholar
• Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 2000;18:2169–2178.
   PubMed Web of Science ®Google Scholar
• Schultz-Hector S, Kallfass E, Sund M. [Radiation sequelae in the large arteries. A review of clinical and experimental data]. Strahlenther Onkol 1995;171:427–436.
   PubMedGoogle Scholar
• Knighton DR, Hunt TK, Scheuenstuhl H, et al. Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science 1983;221:1283–1285.
   PubMed Web of Science ®Google Scholar
• Van Putten JW, Schlosser NJ, Vujaskovic Z, et al. Superior vena cava obstruction caused by radiation induced venous fibrosis. Thorax 2000;55:245–246.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Williamson RC. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 1999;25:239–243.
   PubMed Web of Science ®Google Scholar
• Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078–3083.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484–3488.
   PubMed Web of Science ®Google Scholar
• Merkow RP, Bilimoria KY, McCarter MD, et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg 2011;254:131–137.
   PubMed Web of Science ®Google Scholar
• Hill SL, Berry RE. Subclavian vein thrombosis: a continuing challenge. Surgery 1990;108:1–9.
   PubMed Web of Science ®Google Scholar
• Burihan E, de Figueiredo LF, Francisco Junior J, et al. Upper-extremity deep venous thrombosis: analysis of 52 cases. Cardiovasc Surg 1993;1:19–22.
   PubMedGoogle Scholar
• Stephens LC, Haire WD, Kotulak GD. Are clinical signs accurate indicators of the cause of central venous catheter occlusion?JPEN J Parenter Enteral Nutr 1995;19:75–79.
   PubMed Web of Science ®Google Scholar
• Merminod T, Pellicciotta S, Bounameaux H. Limited usefulness of D-dimer in suspected deep vein thrombosis of the upper extremities. Blood Coagul Fibrinolysis 2006;17:225–226.
   PubMed Web of Science ®Google Scholar
• Baarslag HJ, van Beek EJ, Koopman MM, et al. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. Ann Intern Med 2002;136:865–872.
   PubMed Web of Science ®Google Scholar
• Baxter GM, Kincaid W, Jeffrey RF, et al. Comparison of colour Doppler ultrasound with venography in the diagnosis of axillary and subclavian vein thrombosis. Br J Radiol 1991;64:777–781.
   PubMed Web of Science ®Google Scholar
• Mustafa BO, Rathbun SW, Whitsett TL, et al. Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review. Arch Intern Med 2002;162: 401–404.
   PubMed Web of Science ®Google Scholar
• Koksoy C, Kuzu A, Kutlay J, et al. The diagnostic value of colour Doppler ultrasound in central venous catheter related thrombosis. Clin Radiol 1995;50:687–689.
   PubMed Web of Science ®Google Scholar
• Gaitini D, Beck-Razi N, Haim N, et al. Prevalence of upper extremity deep venous thrombosis diagnosed by color Doppler duplex sonography in cancer patients with central venous catheters. J Ultrasound Med 2006;25:1297–1303.
   PubMed Web of Science ®Google Scholar
• Kroencke TJ, Taupitz M, Arnold R, et al. Three-dimensional gadolinium-enhanced magnetic resonance venography in suspected thrombo-occlusive disease of the central chest veins. Chest 2001;120:1570–1576.
   PubMed Web of Science ®Google Scholar
• Burns KE, McLaren A. A critical review of thromboembolic complications associated with central venous catheters. Can J Anaesth 2008;55:532–541.
   PubMed Web of Science ®Google Scholar
• Kahn SR, Ginsberg JS. The post-thrombotic syndrome: current knowledge, controversies, and directions for future research. Blood Rev 2002;16:155–165.
   PubMed Web of Science ®Google Scholar
• Elman EE, Kahn SR. The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review. Thromb Res 2006;117:609–614.
   PubMed Web of Science ®Google Scholar
• Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996;75:251–253.
   PubMed Web of Science ®Google Scholar
• De Cicco M, Matovic M, Balestreri L, et al. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. Ann Oncol 2009; 20:1936–1942.
   PubMed Web of Science ®Google Scholar
• Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005;23:4057–4062.
   PubMed Web of Science ®Google Scholar
• Karthaus M, Kretzschmar A, Kroning H, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006;17:289–296.
   PubMed Web of Science ®Google Scholar
• Young AM, Billingham LJ, Begum G, et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009;373:567–574.
   PubMed Web of Science ®Google Scholar
• Akl EA, Vasireddi SR, Gunukula S, et al. Anticoagulation for patients with cancer and central venous catheters. Cochrane Database Syst Rev 2011;(4):CD006468.
   Google Scholar
• Mismetti P, Mille D, Laporte S, et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 2003;88:67–73.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl.):e419S–e494S.
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines Version 1.2013. Venous thromboembolic disease. 2013. Available from: www.nccn.org
   Google Scholar
• Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729–1735.
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349: 146–153.
   PubMed Web of Science ®Google Scholar
• Akl EA, Barba M, Rohilla S, et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008;(2):CD006650.
   Google Scholar
• van Doormaal FF, Cohen AT, Davidson BL, et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thromb Haemost 2010;104:86–91.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342–2352.
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363: 2499–2510.
   PubMed Web of Science ®Google Scholar
• Kovacs MJ, Kahn SR, Rodger M, et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007;5:1650–1653.
   PubMed Web of Science ®Google Scholar
• Baskin JL, Pui CH, Reiss U, et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet 2009;374:159–169.
   PubMed Web of Science ®Google Scholar
• Spence LD, Gironta MG, Malde HM, et al. Acute upper extremity deep venous thrombosis: safety and effectiveness of superior vena caval filters. Radiology 1999;210:53–58.
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, van't Hek LG, Vlasveld LT, et al. Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator. Thorax 1993;48: 558–559.
   PubMed Web of Science ®Google Scholar
• Schindler J, Bona RD, Chen HH, et al. Regional thrombolysis with urokinase for central venous catheter-related thrombosis in patients undergoing high-dose chemotherapy with autologous blood stem cell rescue. Clin Appl Thromb Hemost 1999;5:25–29.
   PubMed Web of Science ®Google Scholar
• Kim HS, Preece SR, Black JH, et al. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vasc Surg 2008;47:388–394.
   PubMed Web of Science ®Google Scholar